Finding a way to slow or even stop Alzheimer’s disease is one of the most difficult challenges facing medicine today. Many research and clinical trials have led to promising results over the years, while others have produced disappointing findings. But what if there were a way to get more out of these trials—even the ones with less-than-promising results? What if there were a better way to determine if a drug is hitting its intended target?
To improve the survival of patients with brain tumors, Vidya Chandramohan, PhD, focuses on developing bacterial toxin-based therapies for glioblastoma.
For patients who find themselves slowly beginning to lose vision, today’s doctors have gene replacement therapy as a treatment option. However, there’s a small window of time when the therapy will work best, meaning if a patient isn’t seen soon enough, vision cannot be restored.
Gifts from generous donors have helped researchers who are working to answer basic questions about the human brain—answers that could lead to important discoveries in disease and improve patient outcomes.
In 2021, a baby boy named Easton Sinnamon was the first person in the world to receive a combination heart transplant and allogeneic processed thymus tissue implantation. Six months later, a video showed Easton smiling and playing in a high chair, and tests indicated that the processed thymus tissue was working: building the T cells needed for a well-functioning immune system.